Celgene nails down a 'transformational' $7.2B Receptos buyout; Lilly, Boehringer roll out Lantus in first big market;

@FierceBiotech: UPDATED: Amgen gets a big win with FDA OK for PCSK9 cholesterol drug. Article | Follow @FierceBiotech

@JohnCFierce: Eli Lilly's marginal cancer drug becomes Exhibit A in pricing dilemma. Report | Follow @JohnCFierce

> Celgene ($CELG) has closed on its $7.2 billion buyout of Receptos. "The Receptos acquisition provides a transformational opportunity for Celgene to impact multiple therapeutic areas," said Celgene CEO Bob Hugin. "This acquisition enhances our I&I portfolio and allows us to leverage the investments made in our global organization to accelerate our growth in the medium and long-term." Release

> Eli Lilly ($LLY) and Boehringer Ingelheim have rolled out their biosimilar version of Lantus in its first major market. The U.K. launch follows some smaller rollouts in Eastern Europe--and it's the next move in a planned worldwide assault on the Sanofi ($SNY) diabetes stalwart. Story

Medical Device News

@FierceMedDev: FDA scolds Cepheid for manufacturing issues in Sweden. FierceDiagnostics story | Follow @FierceMedDev

@VarunSaxena2: Updated $ABT's interest in $STJ w/ info from old article on their prior partnership. Neat to add context from 2012. Article | Follow @VarunSaxena2

@EmilyWFierce: ICYMI yesterday: J&J and PCH launch hardware startup accelerator. Story | Follow @EmilyWFierce

> Nerve repair micro-cap AxoGen nabs $17.5M from PE group to get to cash-flow positive. More

> Recall roundup: CareFusion infusion pump, J&J sedation device, Teleflex endobronchial tube. Story

> DOD chips in for $171M Silicon Valley flexible electronics project. Article

Pharma News

@FiercePharma: Patterson shares fall on missed sales and earnings targets. FierceAnimalHealth article | Follow @FiercePharma

@EricPFierce: ICYMI: North Carolina wins Novo prize--$1.2B plant, 700 jobs as Novo builds first US, API plant. Article | Follow @EricPFierce

@CarlyHFierce: Can Sprout's Addyi shrug off serious side effects? These blockbusters did. FiercePharmaMarketing story | Follow @CarlyHFierce

> Celgene nails down $7.2B takeover of Receptos. Item

> J&J brings 500 jobs to Florida with new shared services HQ. More

> Mylan shareholders favor Perrigo takeover. Story

> Sweden's Meda weighs $1B sale of its U.S. business. Article